At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
EXC 001 (currently called PF-06473871)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2, OPEN-LABEL STUDY TO PROVIDE REVISION OF SCARS RESULTING FROM SURGERY IN PRIOR STUDIES OF EXC 001
In Brief
A Phase 2 clinical trial evaluating EXC 001 (currently called PF-06473871) for Reduction in Severity of Skin Scarring. Completed, enrolled 14 participants across 4 sites.
Detailed Summary
The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReduction in Severity of Skin Scarring
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedDec 2011
Primary CompletionSep 2013
TodayJul 2026
First PostedDec 19, 2011
Enrollment StartDec 8, 2011
Primary CompletionSep 10, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.5 years ago
Interventions
EXC 001 (currently called PF-06473871)drug
Single dose administered by injection at four different times